Cargando…

A phase I trial of vertical inhibition of IGF signalling using cixutumumab, an anti-IGF-1R antibody, and selumetinib, an MEK 1/2 inhibitor, in advanced solid tumours

BACKGROUND: We completed a phase I clinical trial to test the safety and toxicity of combined treatment with cixutumumab (anti-IGF-1R antibody) and selumetinib (MEK 1/2 inhibitor). METHODS: Patients with advanced solid tumours, refractory to standard therapy received selumetinib hydrogen sulphate ca...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wilky, B A, Rudek, M A, Ahmed, S, Laheru, D A, Cosgrove, D, Donehower, R C, Nelkin, B, Ball, D, Doyle, L A, Chen, H, Ye, X, Bigley, G, Womack, C, Azad, N S
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2015
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4453594/ https://www.ncbi.nlm.nih.gov/pubmed/25268371 http://dx.doi.org/10.1038/bjc.2014.515

Ejemplares similares

Insulin growth factor receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with metastatic adrenocortical carcinoma
por: Naing, A, et al.
Publicado: (2013)

Update of IGF-1 receptor inhibitor (ganitumab, dalotuzumab, cixutumumab, teprotumumab and figitumumab) effects on cancer therapy
por: Qu, Xiao, et al.
Publicado: (2017)

Correction to: Doxorubicin plus the IGF-1R antibody cixutumumab in soft tissue sarcoma: a phase I study using the TITE-CRM model
por: Chugh, R., et al.
Publicado: (2019)

Cixutumumab reveals a critical role for IGF-1 in adipose and hepatic tissue remodelling during the development of diet-induced obesity
por: Imrie, Helen, et al.
Publicado: (2022)

Development and preclinical evaluation of cixutumumab drug conjugates in a model of insulin growth factor receptor I (IGF-1R) positive cancer
por: Solomon, Viswas Raja, et al.
Publicado: (2020)

Skeletal muscle anabolism is a side effect of therapy with the MEK inhibitor: selumetinib in patients with cholangiocarcinoma
por: Prado, C M M, et al.
Publicado: (2012)

Phase I trial of the MEK inhibitor selumetinib in combination with thoracic radiotherapy in non-small cell lung cancer
por: Haslett, K., et al.
Publicado: (2021)

Association analysis of the IGF1 gene with childhood growth, IGF-1 concentrations and type 1 diabetes
por: Vella, A., et al.
Publicado: (2008)

The MEK inhibitor selumetinib complements CTLA-4 blockade by reprogramming the tumor immune microenvironment
por: Poon, Edmund, et al.
Publicado: (2017)

IGF-1R inhibition induces MEK phosphorylation to promote survival in colon carcinomas
por: Wang, Qing, et al.
Publicado: (2020)

Circulating IGF1 and IGF2 and SNP genotypes in men and pregnant and non-pregnant women
por: Gatford, K L, et al.
Publicado: (2014)

IGF1R/IR Mediates Resistance to BRAF and MEK Inhibitors in BRAF-Mutant Melanoma
por: Patel, Hima, et al.
Publicado: (2021)

Phase II study of selumetinib, an orally active inhibitor of MEK1 and MEK2 kinases, in KRAS(G12R)-mutant pancreatic ductal adenocarcinoma
por: Kenney, Cara, et al.
Publicado: (2021)

A randomised phase II trial of selumetinib vs selumetinib plus temsirolimus for soft-tissue sarcomas
por: Eroglu, Z, et al.
Publicado: (2015)

Does Reduced IGF-1R Signaling in Igf1r (+/−) Mice Alter Aging?
por: Bokov, Alex F., et al.
Publicado: (2011)

Pharmacokinetics and pharmacogenetics of the MEK1/2 inhibitor, selumetinib, in Asian and Western healthy subjects: a pooled analysis
por: Dymond, Angela W., et al.
Publicado: (2017)

IGF2 and IGF1R mRNAs Are Detectable in Human Spermatozoa
por: Cannarella, Rossella, et al.
Publicado: (2020)

The MEK1/2 inhibitor, selumetinib (AZD6244; ARRY-142886), enhances anti-tumour efficacy when combined with conventional chemotherapeutic agents in human tumour xenograft models
por: Holt, S V, et al.
Publicado: (2012)

Enhanced response of melanoma cells to MEK inhibitors following unbiased IGF-1R down-regulation
por: Suleymanova, Naida, et al.
Publicado: (2017)

Des(1–3)IGF-1 Treatment Normalizes Type 1 IGF Receptor and Phospho-Akt (Thr 308) Immunoreactivity in Predegenerative Retina of Diabetic Rats
por: Kummer, A., et al.
Publicado: (2003)

Associations among IGF-1, IGF2, IGF-1R, IGF-2R, IGFBP-3, insulin genetic polymorphisms and central precocious puberty in girls
por: Chang, Hua-Pin, et al.
Publicado: (2018)

SP1-induced lncRNA MCF2L-AS1 promotes cisplatin resistance in ovarian cancer by regulating IGF2BP1/IGF2/MEK/ERK axis
por: Zhu, Yan, et al.
Publicado: (2022)

Ex vivo treatment of patient biopsies as a novel method to assess colorectal tumour response to the MEK1/2 inhibitor, Selumetinib
por: Novo, Sonia M., et al.
Publicado: (2017)

Regulation of MEK inhibitor selumetinib sensitivity by AKT phosphorylation in the novel BRAF L525R mutant
por: Nakai, Chikako, et al.
Publicado: (2023)

The selective MEK1 inhibitor Selumetinib enhances the antitumor activity of everolimus against renal cell carcinoma in vitro and in vivo
por: Zou, Yun, et al.
Publicado: (2017)

Damaging missense variants in IGF1R implicate a role for IGF-1 resistance in the etiology of type 2 diabetes
por: Gardner, Eugene J., et al.
Publicado: (2022)

The IGF-1/IGF-1R signaling axis in the skin: a new role for the dermis in aging-associated skin cancer
por: Lewis, Davina A., et al.
Publicado: (2009)

Looking at IGF-1 through the hourglass
por: Zhang, William B., et al.
Publicado: (2022)

Addiction to the IGF2-ID1-IGF2 circuit for maintenance of the breast cancer stem-like cells
por: Tominaga, K, et al.
Publicado: (2017)

Relation of the IGF/IGF1R system to autophagy in colitis and colorectal cancer
por: Sipos, Ferenc, et al.
Publicado: (2017)

Autocrine IGF-1 Action in Adipocytes Controls Systemic IGF-1 Concentrations and Growth
por: Klöting, Nora, et al.
Publicado: (2008)

Cyclic glycine-proline regulates IGF-1 homeostasis by altering the binding of IGFBP-3 to IGF-1
por: Guan, Jian, et al.
Publicado: (2014)

The MEK-Inhibitor Selumetinib Attenuates Tumor Growth and Reduces IL-6 Expression but Does Not Protect against Muscle Wasting in Lewis Lung Cancer Cachexia
por: Au, Ernie D., et al.
Publicado: (2017)

A prospective study of serum insulin-like growth factor-I (IGF-I), IGF-II, IGF-binding protein-3 and breast cancer risk
por: Allen, N E, et al.
Publicado: (2005)

IGF-1 facilitates extinction of conditioned fear
por: Maglio, Laura E, et al.
Publicado: (2021)

Acute tumour response to the MEK1/2 inhibitor selumetinib (AZD6244, ARRY-142886) evaluated by non-invasive diffusion-weighted MRI
por: Beloueche-Babari, M, et al.
Publicado: (2013)

Connecting the Dots Between the Gut–IGF-1–Prostate Axis: A Role of IGF-1 in Prostate Carcinogenesis
por: Matsushita, Makoto, et al.
Publicado: (2022)

Identification of insulin-like growth factor (IGF)-I and IGF-binding protein in chylous ascites.
por: Lee, D. Y.
Publicado: (1998)

Targeting IGF-1R: throwing out the baby with the bathwater?
por: Basu, B, et al.
Publicado: (2011)

Investigation of Igf-1, Igf-Bp3 and Igf-Bp5 levels in umbilical cord blood of infants with developmental dysplasia of the hip
por: DEMİREL, Esra, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_sd23o0dm0vtqe2nqripsaafojh